Nkarta announced the promotion of David Shook, to the role of CMO. Shook has expertise in cell therapy development and continues to lead Nkarta’s global clinical development and regulatory operations. Shook joined Nkarta in 2020 and was appointed as VP, clinical development in 2022.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NKTX:
- Nkarta Promotes David R. Shook, M.D., to Chief Medical Officer
- Nkarta downgraded to Perform from Outperform at Oppenheimer
- Nkarta price target lowered to $26 from $36 at Oppenheimer
- Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
- Nkarta announces updated clinical data on NKX019
